

Silvia Sartorelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1841230/publications.pdf>

Version: 2024-02-01

33
papers

441
citations

1039880

9
h-index

794469

19
g-index

33
all docs

33
docs citations

33
times ranked

857
citing authors

#	ARTICLE	IF	CITATIONS
1	Arrhythmias in myocarditis: State of the art. Heart Rhythm, 2019, 16, 793-801.	0.3	142
2	Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. Annals of the Rheumatic Diseases, 2020, 79, 1252-1253.	0.5	51
3	Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. Rheumatology, 2020, 59, 2523-2533.	0.9	35
4	Impact of systemic immune-mediated diseases on clinical features and prognosis of patients with biopsy-proved myocarditis. International Journal of Cardiology, 2019, 280, 110-116.	0.8	33
5	Therapeutic strategies for virus-negative myocarditis: a comprehensive review. European Journal of Internal Medicine, 2020, 77, 9-17.	1.0	30
6	Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. Journal of Autoimmunity, 2021, 116, 102545.	3.0	25
7	Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. Seminars in Arthritis and Rheumatism, 2020, 50, 509-514.	1.6	24
8	Efficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: A prospective cohort study. Journal of Autoimmunity, 2020, 106, 102330.	3.0	20
9	Telemedicine in myocarditis: Evolution of a multidisciplinary "disease unit" at the time of COVID-19 pandemic. American Heart Journal, 2020, 229, 121-126.	1.2	17
10	Revisiting characteristics, treatment and outcome of cardiomyopathy in eosinophilic granulomatosis with polyangiitis (formerly Churg's "Strauss"). Rheumatology, 2022, 61, 1175-1184.	0.9	11
11	A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM). Frontiers in Medicine, 2021, 8, 723506.	1.2	10
12	Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation. Rheumatology, 2022, 61, 4409-4419.	0.9	10
13	Large-vessel Vasculitis Affecting the Aorta and its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature. Journal of Rheumatology, 2020, 47, 1780-1784.	1.0	9
14	Response to: "Correspondence on "Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey" by Comarmond et al". Annals of the Rheumatic Diseases, 2023, 82, e31-e31.	0.5	8
15	Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance. Journal of Clinical Rheumatology, 2019, Publish Ahead of Print, .	0.5	7
16	AB0621...GENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASU ARTERITIS. , 2019, , .		2
17	Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study. Rheumatology, 2022, 62, 341-346.	0.9	2
18	FRI0278...OFF-LABEL USE OF BIOLOGICAL THERAPIES IN RELAPSING AND/OR REFRACTORY EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS). , 2019, , .		1

#	ARTICLE	IF	CITATIONS
19	Clinically isolated aortitis successfully treated with methotrexate monotherapy. <i>Rheumatology</i> , 2020, 59, e54-e56.	0.9	1
20	Clinical and dermoscopic description of accelerated nodulosis after tocilizumab treatment for an isolated aortitis with coronary involvement. <i>International Journal of Dermatology</i> , 2021, 60, e359-e361.	0.5	1
21	Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 129-134.	0.4	1
22	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 695-695.	0.4	1
23	357.â€fEFFICACY AND SAFETY OF TOCILIZUMAB IN GIANT CELL ARTERITIS: A MONOCENTRIC REAL-LIFE EXPERIENCE. <i>Rheumatology</i> , 2019, 58, .	0.9	0
24	168.â€fGENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASUâ€™S ARTERITIS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
25	273.â€fTAKAYASUâ€™S ARTERITIS: BEYOND THE VESSELS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
26	288.â€fDRUG RETENTION AND DISCONTINUATION REASONS BETWEEN EIGHT BIOLOGICS IN PATIENTS WITH TAKAYASUâ€™S ARTERITIS: A SINGLE-CENTER EXPERIENCE. <i>Rheumatology</i> , 2019, 58, .	0.9	0
27	Diagnostic approach and novel therapeutic option for cardiac inflammatory disorders. Comment on "Antisynthetase syndrome and cardiac involvement: a rare association" by Meudec et al. <i>Joint Bone Spine</i> 2018. doi: 10.1016/j.jbspin.2018.09.019. <i>Joint Bone Spine</i> , 2019, 86, 407.	0.8	0
28	AB0613â€fPRESENTATION OF TAKAYASU ARTERITIS ACCORDING TO THE AGE OF ONSET IN A MONOCENTRIC ITALIAN COHORT. , 2019, , .		0
29	AB0620â€fEFFICACY AND SAFETY OF TOCILIZUMAB IN GIANT CELL ARTERITIS: A MONOCENTRIC REAL-LIFE EXPERIENCE. , 2019, , .		0
30	THU0570â€fEFFICACY AND SAFETY OF ANAKINRA IN THE TREATMENT OF AUTOIMMUNE MYOCARDITIS. , 2019, , .		0
31	SAT0221â€fOFF-LABEL USE OF BIOLOGICAL THERAPIES IN RELAPSING AND/OR REFRACTORY POLYARTERITIS NODOSA. , 2019, , .		0
32	THU0319â€fTAKAYASUâ€™S ARTERITIS: BEYOND THE VESSELS. , 2019, , .		0
33	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 695.	0.4	0